Adverse event comparison between glucagon‐like peptide‐1 receptor agonists and other antiobesity medications following bariatric surgery

Documenti analoghi

• Real‐world titration, persistence & weight loss of semaglutide and tirzepatide in an academic obesity clinic
  di: Jason M. Samuels, et al.
  Pubblicazione: (2025)
• Risks of peri‐ and postoperative complications with glucagon‐like peptide‐1 receptor agonists
  di: David C. Klonoff, et al.
  Pubblicazione: (2024)
• Suicidality among users of glucagon‐like peptide‐1 receptor agonists: An emerging signal?
  di: Darren Lau, et al.
  Pubblicazione: (2024)
• A long‐acting glucose‐dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon‐like peptide‐1 receptor agonist therapy
  di: Filip K. Knop, et al.
  Pubblicazione: (2024)
• Real‐world use of glucagon‐like peptide‐1 receptor agonists in youth with type 2 diabetes is associated with short‐term improvements in HbA1c
  di: Stephanie L. Samuels, et al.
  Pubblicazione: (2024)